MX2020002741A - Uso de gaboxadol en el tratamiento de narcolepsia. - Google Patents

Uso de gaboxadol en el tratamiento de narcolepsia.

Info

Publication number
MX2020002741A
MX2020002741A MX2020002741A MX2020002741A MX2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A
Authority
MX
Mexico
Prior art keywords
narcolepsy
gaboxadol
treatment
compositions
sub
Prior art date
Application number
MX2020002741A
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2020002741A publication Critical patent/MX2020002741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2020002741A 2017-09-12 2018-09-11 Uso de gaboxadol en el tratamiento de narcolepsia. MX2020002741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557412P 2017-09-12 2017-09-12
PCT/US2018/050339 WO2019055369A1 (en) 2017-09-12 2018-09-11 USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA

Publications (1)

Publication Number Publication Date
MX2020002741A true MX2020002741A (es) 2020-07-21

Family

ID=65630168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002741A MX2020002741A (es) 2017-09-12 2018-09-11 Uso de gaboxadol en el tratamiento de narcolepsia.

Country Status (10)

Country Link
US (2) US20190076409A1 (cg-RX-API-DMAC7.html)
EP (1) EP3661507A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020533415A (cg-RX-API-DMAC7.html)
KR (1) KR20200053570A (cg-RX-API-DMAC7.html)
CN (1) CN111328282A (cg-RX-API-DMAC7.html)
AU (1) AU2018331326A1 (cg-RX-API-DMAC7.html)
CA (1) CA3075478A1 (cg-RX-API-DMAC7.html)
IL (1) IL272962A (cg-RX-API-DMAC7.html)
MX (1) MX2020002741A (cg-RX-API-DMAC7.html)
WO (1) WO2019055369A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018331326A1 (en) * 2017-09-12 2020-03-19 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
WO2020259787A1 (en) 2019-06-28 2020-12-30 University Of Copenhagen Treatment of cns disorders with sleep disturbances
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20250375429A1 (en) 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200528098A (en) * 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
US9480695B2 (en) * 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
RU2019114940A (ru) * 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
CA3025473A1 (en) * 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
AU2018331326A1 (en) * 2017-09-12 2020-03-19 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy

Also Published As

Publication number Publication date
AU2018331326A1 (en) 2020-03-19
EP3661507A4 (en) 2020-11-18
US20190076409A1 (en) 2019-03-14
KR20200053570A (ko) 2020-05-18
CA3075478A1 (en) 2019-03-21
US20200222372A1 (en) 2020-07-16
WO2019055369A1 (en) 2019-03-21
JP2020533415A (ja) 2020-11-19
IL272962A (en) 2020-04-30
CN111328282A (zh) 2020-06-23
EP3661507A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
EA201791882A1 (ru) Агонисты 5ht для лечения нарушений
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
JOP20200230B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX389702B (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
HK1245078A1 (zh) 治疗神经退行性疾病的方法
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
GEP20247585B (en) Furoindazole derivatives
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
TW201613578A (en) Pharmaceutical combinations
PH12021550671A1 (en) Prodrugs of cgrp antagonists
WO2016168553A8 (en) Deuterated obeticholic acid
PL3348547T3 (pl) Pochodne benzimidazolu jako inhibitory NAV 1.7 (kanał sodowy, bramkowany napięciem, typ IX, podjednostka alfa (SCN9A)) do leczenia bólu, dysurii i stwardnienia rozsianego
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2017009110A (es) Terapia de combinacion para hipertension pulmonar.
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
MX2023012415A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора